Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H15F3N4O5 |
| Molecular Weight | 436.3414 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][N+](=O)C1=CN2C[C@@H](COC2=N1)OCC3=CC=C(N=C3)C4=CC=C(OC(F)(F)F)C=C4
InChI
InChIKey=ZXSGSFMORAILEY-HNNXBMFYSA-N
InChI=1S/C19H15F3N4O5/c20-19(21,22)31-14-4-2-13(3-5-14)16-6-1-12(7-23-16)10-29-15-8-25-9-17(26(27)28)24-18(25)30-11-15/h1-7,9,15H,8,10-11H2/t15-/m0/s1
| Molecular Formula | C19H15F3N4O5 |
| Molecular Weight | 436.3414 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.tballiance.org/news/tb-alliance-advances-next-generation-tb-drug-candidate-clinical-testing
Curator's Comment: Description was created based on several sources, including https://www.tballiance.org/news/tb-alliance-advances-next-generation-tb-drug-candidate-clinical-testing
TBA-354, also known as SN31354, is a potent anti-tuberculosis drug candidate. TBA-354 is narrow spectrum and bactericidal in vitro against replicating and nonreplicating Mycobacterium tuberculosis, with potency similar to that of delamanid and greater than that of PA-824. TBA-354 maintains activity against Mycobacterium tuberculosis H37Rv isogenic monoresistant strains and clinical drug-sensitive and drug-resistant isolates. TBA-354 is a promising next-generation nitroimidazole antitubercular agent. TBA-354 emerged from studies designed to identify a next generation nitroimidazole for TB. TB Alliance conducted the studies in collaboration with the University of Auckland and University of Illinois-Chicago. Once identified, TB Alliance further advanced TBA-354 through pre-clinical development and is now the sponsor of the Phase 1 study.
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2049 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28859520 |
20 mg/kg single, intraperitoneal dose: 20 mg/kg route of administration: Intraperitoneal experiment type: SINGLE co-administered: |
TBA-354 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10135 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28859520 |
20 mg/kg single, intraperitoneal dose: 20 mg/kg route of administration: Intraperitoneal experiment type: SINGLE co-administered: |
TBA-354 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.24 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28859520 |
20 mg/kg single, intraperitoneal dose: 20 mg/kg route of administration: Intraperitoneal experiment type: SINGLE co-administered: |
TBA-354 plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25331696 |
unknown, unknown |
TBA-354 plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:36:35 GMT 2023
by
admin
on
Sat Dec 16 11:36:35 GMT 2023
|
| Record UNII |
911T37M2WY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
49836057
Created by
admin on Sat Dec 16 11:36:35 GMT 2023 , Edited by admin on Sat Dec 16 11:36:35 GMT 2023
|
PRIMARY | |||
|
1403987-02-9
Created by
admin on Sat Dec 16 11:36:35 GMT 2023 , Edited by admin on Sat Dec 16 11:36:35 GMT 2023
|
NO STRUCTURE GIVEN | |||
|
911T37M2WY
Created by
admin on Sat Dec 16 11:36:35 GMT 2023 , Edited by admin on Sat Dec 16 11:36:35 GMT 2023
|
PRIMARY | |||
|
1257426-19-9
Created by
admin on Sat Dec 16 11:36:35 GMT 2023 , Edited by admin on Sat Dec 16 11:36:35 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
MIC
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Official Title: A Phase I, Double-Blind, Placebo Controlled, Randomized, Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
Purpose: The objective of the study is to evaluate the safety and tolerability of multiple doses of TBA-354 in healthy subjects.
|
||
|
ACTIVE MOIETY |
TBA-354 MICs and MBCs against M. tuberculosis H37Rv: MIC (replicating) = 0.006 .MU.M, MBC (replicating) = 0.006 .MU.M, LORA (NR) MIC = 0.27 .MU.M, LORA (NR) MBC = 3.4 .MU.M, 4% BSAb MIC (replicating) = 0.011 .MU.M, 10% FBSc MIC (replicating) = 0.012 .MU.M
|
||
|
ACTIVE MOIETY |
Originator: Global Alliance for TB Drug Development, University of Auckland; Developer: Global Alliance for TB Drug Development; Class: Antitubercular, Nitroimidazole, Oxazine, Pyridine, Small molecule; Mechanism of Action: Undefined mechanism; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Tuberculosis; Most Recent Events: 19 Nov 2015 Global Alliance for TB Drug Development plans a phase I trial in Healthy volunteers in USA (NCT02606214), 01 Jan 2015 Phase-I clinical trials in Tuberculosis (In volunteers) in USA (PO), 12 Sep 2012 Pharmacodynamics & pharmacokinetics data from preclinical studies in Tuberculosis presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012)
|
